Previous studies have shown that antagonists of bombesin/gastrin-releasing peptide (GRP) inhibit the growth of various cancers by interfering with the growth-stimulatory effects of bombesin-like peptides, and reducing the levels of epidermal growth factor (Schally et al, 2001). Here, GRP is linked to cancer.